Summary: Psychedelics in Psychiatry — A Wakeup Call for Clinicians in the Age of Policy Reform
Type: Letter to the Editor Authors: Shobit Garg and Amrit Pattojoshi (psychiatrists, India) Journal: Primary Care Companion for CNS Disorders, 2026;28(5):26lr04256 Published: 20 October 2026 DOI: https://doi.org/10.4088/PCC.26lr04256
The core argument
A US executive order signed on 18 April 2026 told the Food and Drug Administration (FDA) to fast-track its review of psychedelic drugs, naming psilocybin and ibogaine, and set aside $50 million for clinical development. The authors say this moves psychedelics into mainstream medicine, and that doctors, rather than politicians or media personalities, should now steer the field using evidence and ethics.
Evidence they cite
| Drug |
Condition |
What the trials showed |
| Psilocybin with therapy |
Major depression |
Large benefit, still present at 4 weeks; roughly matched the antidepressant escitalopram on the main measure, with secondary measures leaning psilocybin's way |
| MDMA with therapy |
Post-traumatic stress disorder (PTSD) |
Clear symptom reduction versus placebo in a late-stage (phase 3) trial |
| Ketamine |
Treatment-resistant depression |
Rapid antidepressant effect |
| Low-dose LSD (microdosing) |
Healthy adults |
Physically safe with measurable short-term effects, but no lasting mood or thinking benefit shown yet |
The ibogaine warning
- Ibogaine shows promise for PTSD and opioid dependence in veterans.
- It can also disturb heart rhythm (it lengthens the QT interval, a phase of the heartbeat's electrical cycle) and has been linked to sudden deaths in treatment settings. This is why the FDA previously held back.
- Moving it out of Schedule I (the most restricted US drug category) would make research easier, which the authors welcome, but they insist that speed must not replace a careful safety process.
- Their historical point: the first psychedelic wave failed partly because excitement ran ahead of the data.
Implications for India
- India's Narcotic Drugs and Psychotropic Substances Act of 1985 still tightly limits this research.
- With the US, long the main enforcer of strict scheduling, now promoting these treatments, the authors think reform is politically more achievable.
- They urge the Indian Psychiatric Society and the national drug regulator to build on a 2014 amendment that created a medical-use category of "essential narcotic drugs".
What they say clinicians must insist on
- Screening patients beforehand for vulnerability to psychosis and bipolar disorder, which psychedelics can trigger or worsen.
- Structured settings with trained staff, treated as part of the treatment itself.
- Keeping three things separate in public discussion: supervised therapeutic use, experimental microdosing, and recreational misuse.
Bottom line
The authors see the policy shift as real and irreversible, and want it built on evidence and patient safety instead of political momentum.
Notes on the source
- This is an opinion letter, not new research; it draws on 10 references that were not included in the supplied text.
- The authors declare no funding or financial interests, and state that AI tools were used for language refinement.